Clinical trial • Not applicable • Oncology

Monobenzon for Malignant melanoma | Advanced or metastatic melanoma

Not applicable trial of Monobenzon for Malignant melanoma | Advanced or metastatic melanoma. 18 participants.

Overview

Trial Therapeutic Area
Oncology
Trial Disease
Malignant melanoma | Advanced or metastatic melanoma
Trial Stage
Not applicable
Drug Modality
Small molecule

Key dates

Initial CTIS Submission Date
12-01-2026
First CTIS Authorization Date
13-04-2026

Trial design

Not applicable trial across 1 site in Netherlands.

Target Sample Size
18

Recruitment

Planned Sample Size
18
Recruitment Window Months
24

Geography

Total Number Of Sites
1
Total Number Of Participants
18

Netherlands

Earliest CTIS Part Ii Submission Date
10-03-2026
Latest Decision Or Authorization Date
13-04-2026
Processing Time Days
34
Number Of Sites
1
Number Of Participants
18

Sites

Site Name
Amsterdam UMC Stichting
Department Name
Medische oncologie
Contact Person Name
Mariette Labots
Contact Person Email
m.labots@amsterdamumc.nl
Number Of Participants
18

Sponsor

Primary sponsor

Full Name
Amsterdam UMC Stichting
Organisation Type
Patient organisation/association
Country Of Registered Address
Netherlands

Investigational products

Investigational Product Name
Monobenzon
Active Substance
Monobenzon
Modality
Small molecule
Routes Of Administration
Topical (cream)
Route
Topical
Investigational Product Name
Imiquimod
Active Substance
Imiquimod
Modality
Small molecule
Routes Of Administration
Topical (cream)
Route
Topical
Combination Treatment
Yes

Related trials

Other published trials that may interest you.